Palatin Technologies (PTN) Retained Earnings (2011 - 2026)
Palatin Technologies' (PTN) quarterly Retained Earnings came in at -$463.1 million in Q1 2026, down 1.37% YoY from -$469.5 million in Q1 2025, and down 197.88% on a QoQ basis from $473.1 million in Q4 2025.
Palatin Technologies (PTN) Retained Earnings (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Retained Earnings data on file, last reported at -$463.1 million in Q1 2026.
- Quarterly Retained Earnings fell 1.37% year-over-year to -$463.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$463.1 million (down 1.37% YoY) and the FY2025 annual result came in at -$459.1 million, down 3.92% from the prior year.
- Retained Earnings slipped to -$463.1 million in Q1 2026, from $473.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $473.1 million in Q4 2025 to a low of -$463.1 million in Q1 2026.
- A 5-year average of $23.2 million and a median of $401.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 212.6% — and 2024, when it plunged 209.3%.
- Tracing PTN's Retained Earnings over 5 years: stood at $413.9 million in 2022, then retreated by 0.09% to $413.6 million in 2023, then sank by 209.3% to -$452.0 million in 2024, then soared by 204.66% to $473.1 million in 2025, then tumbled by 197.88% to -$463.1 million in 2026.
- The last three Retained Earnings figures came in at -$463.1 million (Q1 2026), $473.1 million (Q4 2025), and $454.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 473.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -463.09 Mn |
| Dec 31, 2025 | 473.11 Mn |
| Sep 30, 2025 | 454.78 Mn |
| Jun 30, 2025 | -459.07 Mn |
| Mar 31, 2025 | -456.84 Mn |
| Dec 31, 2024 | -452.03 Mn |
| Sep 30, 2024 | 441.71 Mn |
| Jun 30, 2024 | -441.77 Mn |
| Mar 31, 2024 | 434.93 Mn |
| Dec 31, 2023 | 413.55 Mn |
| Sep 30, 2023 | 416.42 Mn |
| Jun 30, 2023 | -412.03 Mn |
| Mar 31, 2023 | 414.30 Mn |
| Dec 31, 2022 | 413.91 Mn |
| Sep 30, 2022 | -396.25 Mn |
| Jun 30, 2022 | -387.99 Mn |
| Mar 31, 2022 | 400.99 Mn |
| Dec 31, 2021 | -367.59 Mn |
| Sep 30, 2021 | -358.91 Mn |
| Jun 30, 2021 | -351.80 Mn |